Brain scan breakthrough? new tracer targets protein tangles in MSA and Parkinson's

NCT ID NCT06032026

Recruiting now Diagnosis Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new radioactive tracer called 11C-HY-2-15, designed to detect abnormal alpha-synuclein protein in the brain. Researchers will scan 70 adults with multiple system atrophy, Parkinson's disease, progressive supranuclear palsy, or healthy volunteers to see if the tracer can distinguish these conditions. The goal is to improve diagnosis of these brain protein disorders.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 11C-HY-2-15 (a radioactive tracer for PET scans)
What this could lead to: If successful, this could lead to a new way to diagnose and distinguish diseases like multiple system atrophy, Parkinson's, and progressive supranuclear palsy using brain scans.
What could go wrong: This is an early Phase I study with only 70 participants, so the tracer may not reliably detect the intended protein or may have safety issues. Results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SYSTEM ATROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 multiple system atrophy Parkinson disease progressive supranuclear palsy tauopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TAUOPATHIES

Contacts and locations

Locations

University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.